Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 4Recruiting 3Completed 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1

Conditions

Pancreatic Neoplasms 2

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × defactinib × Gastrointestinal × Clear all
NCT03727880 2026-02-04

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02546531 2021-07-20

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Washington University School of Medicine

Phase 1 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡